FDA approves breakthrough pancreatic cancer drug – an oncologist explains how daraxonrasib nearly doubles survival

Pancreatic cancer has been notoriously difficult to target and treat. wildpixel/iStock via Getty Images Plus For a long time, the likelihood of surviving pancreatic cancer has been extremely low. For patients who were diagnosed with metastatic pancreatic cancer between 2015 and 2021, about 97% died within five years of their diagnosis. Pancreatic cancer is so deadly in part because there are no effective screening tests, and it rarely causes noticeable symptoms in its earliest stages. By the…